The Clinical Trials Office (CTO) provides administrative, research and educational services to the Cancer Institute investigators and research staff conducting clinical trials. It serves as the main coordinating center for cancer-related clinical trials from concept development and submission to closure including protocol development, regulatory and compliance guidance, administrative submissions, data collection and data management, data analysis, and quality control functions, and serves as the administrative interface to other clinical research organizations at the NYU Medical Center. The goals of this resource are to: Facilitate clinical trials by providing a framework for development, submission, and conduct of dinical trials. Enhance and facilitate data collection and reporting of clinical cancer research data. Provide educational programs for the CTO staff and clinical investigators. Promote interdisciplinary collaboration and a venue for translating research findings to the clinical arena In response to the previous critique, internal audits, and the review of external consultants, significant changes have occurred within the CTO since the last review. These changes include the appointment of new medical and administrative directors, new standard operating procedures, and restructuring of data management. These improvements have produced a CTO that better meets the needs of investigators performs more effectively within the NYU School of Medicine clinical research environment. Currently, the CTO supervises 49 research staff and manages 158 open protocols. The CTO continues to expand and improve its function to serve as the central coordinating center for the clinical research enterprise at the NYUCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-29
Application #
7843333
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
29
Fiscal Year
2009
Total Cost
$180,896
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Winer, Benjamin Y; Shirvani-Dastgerdi, Elham; Bram, Yaron et al. (2018) Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med 10:
Ruggles, Kelly V; Wang, Jincheng; Volkova, Angelina et al. (2018) Changes in the Gut Microbiota of Urban Subjects during an Immersion in the Traditional Diet and Lifestyle of a Rainforest Village. mSphere 3:
MariƩ, Isabelle J; Chang, Hao-Ming; Levy, David E (2018) HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. J Exp Med 215:3194-3212
Gupta, Ankit; Xu, Jing; Lee, Shirley et al. (2018) Facile target validation in an animal model with intracellularly expressed monobodies. Nat Chem Biol 14:895-900
Lee, Hyun-Wook; Park, Sung-Hyun; Weng, Mao-Wen et al. (2018) E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. Proc Natl Acad Sci U S A 115:E1560-E1569
Evensen, Nikki A; Madhusoodhan, P Pallavi; Meyer, Julia et al. (2018) MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica 103:830-839
Formenti, Silvia C; Rudqvist, Nils-Petter; Golden, Encouse et al. (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24:1845-1851
Sun, Qi; Rabbani, Piul; Takeo, Makoto et al. (2018) Dissecting Wnt Signaling for Melanocyte Regulation during Wound Healing. J Invest Dermatol 138:1591-1600
Gagner, Jean-Pierre; Zagzag, David (2018) Probing Glioblastoma Tissue Heterogeneity with Laser Capture Microdissection. Methods Mol Biol 1741:209-220
Xu, Yang; Taylor, Paul; Andrade, Joshua et al. (2018) Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Res 78:6539-6548

Showing the most recent 10 out of 1170 publications